

Index

a

- abiotic transition metals 310, 332, 335–341
- absorption, distribution, metabolism and excretion (ADME) profiles 464
- acalabrutinib 290
- acetalated dextran 383, 390
- acidic environment 137–138, 466
- Ac₄ManNAz 215, 226, 227, 229, 231
- acoustic impedance 105
- activatable probes 58, 62–68
- activated esters 295–297
- activity-based protein profiling (ABPP) 290, 293
- acylating warheads 295
- acyl-peptide hydrolase (APEH) 297
- administration
 - enteral 42
 - parenteral 42–53
- afatinib 290, 295
- Akaluc 74
- AkaLumine 72, 74
- AlexaFluor680 63–65, 71
- AlexaFluor750 71
- Alexafluor 555 dye 255
- alginate hydrogel modified with tetrazines (HMT) 268
- alkoxy acyl imidazole 284
- alkyne cyclopropanation 332
- allene-caged tyrosine 311
- allylcarbamate (alloc) moiety 324
- α_2 -adrenergic receptor agonist 40
- α -chloroacetamide (CFA) 293
- α -emitter radionuclide therapy 189
- α -emitting nuclides 188–190
- alveolar macrophage targeting 503
- Alzheimer's disease 69, 146, 173–174
- amides 295–297
- amino acid (AA) metabolism 135
- aminoluciferin (AL) 71
- aminopeptidase peptide (APaseP) 467
- anesthesia
 - inhaled agents 38
 - injectable agents 38–40
- angiogenesis 121, 134, 138, 177, 466
- angiopep-2 380, 472
- Animal Research:Reporting *In Vivo* Experiments (ARRIVE) guidelines 33
- annihilation phenomenon 128
- Antares 81
- antibiotic drug ampicillin (AMP) 410
- antibodies 65, 143, 186, 188, 190, 197
- antibody-functionalized NPs 380
- anti-cancer drugs 178, 202, 268, 403, 405, 466
- anti-CD326 antibody 380
- anticonvulsants 40
- antigen-presenting cells (APC) 388, 390, 392, 471, 504
- anti-TAG72 monoclonal antibody CC49 256
- α - or β -emitting radionuclides 143, 186
- apolipoprotein E (ApoE) 177
- apoptosis 134, 139, 143, 186, 412
- arginine-glycine-aspartate (RGD) 454
- aromatic electrophilic substitution reaction 171–172
- ARRIVE guidelines 33

- artificial coelenterazines 81
 artificial metalloenzymes (ArM)
 abiotic transition metals 335–340
 naturally occurring metals 332–335
 aryl fluorosulfate 298, 299
 asialoglycoprotein receptors (ASGP-R)
 492
 asialoorosomuroid (AsOR) 497
 atherosclerotic plaque 145, 177
²¹¹At-labeled compounds 192–193
 atrial natriuretic peptide (ANP) 380
 autofluorescence 57, 61, 472
 autoluminescence 82
 avidin 63–65
 azide-bearing sialic acid glycoconjugates
 215
 azide-bearing sialic acid precursor
 peracetylated
 N-azidoacetylmannosamine
 (Ac₄ManNAz) 215
 azide-cleavable caged fluorophore 331
 azide-dependent fluorescence 231
 8-azido-8-deoxy-Kdo (8AzKdo) 228
 azidohomoalanine 313
 azidosialic acid (SiaNAz) 215, 229, 231
 azidosialic acid-labeled glycans 235
 azidosugar Ac₄ManNAz 226
 azidosugar-loaded glycol chitosan
 nanoparticles 233
 azidothymidine (AZT) 459, 492
 azobenzene 405, 406, 412, 438, 439
 azobenzenze, photoisomerization 440
- b**
- bacillosamine 225
 bacterial cells targeting 505
 BALB/cAnNTac-*Bmp4*^{tm1Bih}[cc] 8
 barbiturate combinations 40
 β-CUBE, SPECT 156
 β-cyclodextrin dye 439
 B6D2F1 4
 beloranib 300
 β-emitting nuclides 186–188
 benzodiazepines 40
 2-benzoylpyridine-Au complexes 319
 β-galactosidase 81
 biarylazacyclooctyne (BARAC) 217
 bicyclo[6.1.0]non-4-yne (BCN) 219
 bimolecular fluorescence
 complementation (BiFC) 68
 biohybrid ArM 335
 bioluminescence 55–58, 69–72, 76, 78,
 81
 bioluminescent enzyme-induced
 electron transfer (BioLeT) 74
 bioluminogenic probes 74, 76, 78, 81,
 83
 “bioluminogenic” substrates 74
 biomimetics 452–454
 bioorthogonal chemistries
 amenable to deployment on cells
 221–223
 suitable for deployment in live
 animals 216–221
 bioorthogonal labeling of proteins 281
 biopanning 454, 456–458
 biotin-appended hCA probe 282
 biphenylcarbonyl-amino (BPC) 508
 2-(4-((bis((1-*tert*-butyl-1*H*-1,2,3-triazol-
 4-yl)methyl)amino)methyl)-
 1*H*-1,2,3-triazol-1-yl) ethyl
 hydrogen sulfate (BTTES) 221
 2,6-bis(propargyloxy)benzyl moiety
 326
 1,2bis(tricoso-10,12-diynoyl)-*sn*-glycero-
 3-phosphocholine (DC_{8,9}PC)
 437
 blood-brain barrier (BBB) 74, 173,
 174, 176, 357, 457, 468, 504
 Bolton–Hunter method 172
 bombesin receptor subtype 2 196
 bond-cleavage reactions 324, 325, 327,
 328, 330, 333
 bond-cleaving bio-orthogonal chemistry
 252, 260–265
 bond-cleaving bio-orthogonal
 ‘click-to-release’ chemistry 251,
 253, 254
 bond formation 86, 294, 299, 319–324
 boron cage compounds 193, 194
 Boron Neutron Capture Therapy
 (BNCT) 185, 203–204
 4-borono-L-phenylalanine (BPA) 204
 bortezomib 300

- B6.129P2-*ApoE*^{tm3(APOE*4)}*Mae*N12 9
 brain macrophage targeting 504–505
 breeding systems and mating systems 19–20
 Bruton's tyrosine kinase (BTK) inhibitors 290
- C**
- caged azidosugar substrate 229
 caged fluorophore 62, 331
 caged luciferin concept 74, 76, 77, 81, 82
 calcein 435–437, 444
 camptothecin (CPT) 403, 466, 467
 cancer diagnosis 134, 135, 138, 142, 147, 148
 cancer imaging 68, 178–180, 224
 cancer stem cells (CSCs) 139, 456
 cancer targeting
 complex glycan scaffold 511–514
 natural monosaccharide-based methods 506–508
 synthetic sugars 508–511
 cancer vaccinations 507
 carbamate-based serine hydrolase inhibitors 297
 carbamates 295–298
 carbohydrate biosynthetic pathways 210, 211, 215, 220, 223–226
 carbohydrate metabolism 134, 224, 491
 carbon nanotubes (CNTs) 141, 391, 392
 5,6-carboxyfluorescein (CF) 435
 cathepsin B-releasable ManNAz analog 229
 cationic endosomolytic polymer (polyethyleneimine) 383
 cell-derived nanosystems 393, 394
 cell-penetrating peptides (CPPs) 324, 380, 466
 cell proliferation 134, 139, 274, 276, 408
 cellular glycans 209–211, 213, 215
 cerebral ischemia 176–177, 504
 Cetuximab 143, 255
 chelating agents for ⁹⁰Y ¹⁷⁷Lu, ²²⁵Ac, and ²¹³Bi 193–195
 chelators 164, 165, 170, 195, 197
 chemiluminescence system 82–84
 chemokine receptor CXCR4 196
 Chinese hamster ovary (CHO) cells 217, 509
 chitosan-coated P*S*i NPs 381
 chitosan-mediated Ac₄ ManNAz delivery 233
 chlorambucil (Cbl) 403, 405
 chloroacetamide-based covalent protein inhibitors 293
 2-chloropropionamide 293
 cholecystokinin-2 (CCK2R)/gastrin receptors 196
 chymotrypsinogen 310, 313
 closed colony 8
 closo-dodecaborate(2-) 193
 clostridium perfringens enterotoxin (C-CPE) 469
 clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 (CRISPR-associated protein 9 nuclease) technology 16, 17
¹¹C-MET (methionine) 146
 coelenterazine-dependent luciferase 76–82
 coenzyme A carboxylase 326
 color Doppler images 108
 commonly used radiotherapeutic agents 197, 198
 complex glycan scaffolds 489, 491, 511
 Complex Object Parametric Analyzer and Sorter (COPAS) 458
 congenic strains 8
 congerin II (sugar-binding lectin) 282
 contemporary PET scanner 129
 contrast agents 109–112, 114, 116, 120
 copper(I)-catalyzed azide alkyne cycloaddition (CuAAC) 323
 copper catalyzed bioconjugation reactions 313
 copper-free click chemistry 216, 239–241

- copper-64-labeled atezolizumab (PET/CT) 179
- coumarinyl ester 404
- ^{11}C -Pittsburgh compound B (^{11}C -PiB) 146
- ^{11}C -raclopride 146
- cre-loxP* system 13–15
- ^{11}C -RWAY-100635 146
- Cu(I) catalyzed azide-alkyne cycloaddition (CuAAC) 221
- Cu(I)-catalyzed Huisgen azide-alkyne cycloaddition (or CuAAC) 313
- Cy5.5 63, 64, 271, 471
- cyanine-based NIR fluorophores Cy5.5 63
- cyanoacrylamide-based BTK inhibitor, PRN1008 293
- cyanoacrylate-based reversible covalent inhibitor 293
- cyclic luciferase concept 84, 86
- cyclopropene-modified sugars 221, 222
- cyclopropene reagents 251
- cyclopropenone-modified proteins 223
- Cy5.5-conjugated antibody 63
- cysteine cathepsins (CTS) 137
- cytotoxic α - or β -emitters 189
- d**
- dacomitinib 290
- DBCO-NIR fluorophore 229
- D2B6F1 4
- decay constants 133
- dendritic cells (DCs) 501, 504
- 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) 225
- detection efficiency of gamma rays 130
- developmental biology 121–123
- D-galactose (Gal) or *N*-acetylgalactosamine (GalNAc) 492
- diarylethene 405, 406
- diazepam 40
- dibenzocyclooctyne 217, 219
- diethylenetriaminepentaacetic acid (DTPA) 179, 180, 193
- digestive enzymes 310, 373
- dimerization 62
- 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) 435, 436
- dioxetane 56
- 1,2-dioxetane scaffold 82, 83
- dioxetanone 56, 70
- dipeptide (DIP) 459
- dipeptidyl peptidase-4 (DPP4) inhibitor 300, 381
- dirhodium-based ArMs 335
- dissociative agent combinations 40
- 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC) 435
- D-luciferin 70–74, 86
- Doppler angle correction 108
- DOTA-NeoBOMB1 196
- Doxil 384
- doxorubicin (Dox) 251, 266, 268, 269, 272, 324, 326, 403, 435, 436
- Dox-TCO 251, 268, 272
- drug discovery 24, 69, 144, 200, 299, 301
- e**
- EKV (ECG-gated Kilohertz Visualization) technology 107
- electrophilic warheads 300
- endogenous and exogenous contrast agents 114, 121
- endogenously expressed native proteins 281
- endogenous protein labeling 281, 287, 288
- endogenous stimuli 381, 401
- EnduRen 82
- energy resolution 131, 132
- enhanced green fluorescent protein 68
- enhanced permeability and retention (EPR) effect 374, 434
- enteral administration 37, 42–44
- Ephrin peptide 468
- epicutaneous administration 46–51
- epidermal growth factor receptor (EGFR) 135, 290, 468
- estrogen receptor 326
- euthanasia 40–41

- ExiTron nano 12000 161
 exogenous stimuli 401
 external beam radiation therapy (RT) 144
 external radiation 185
 extracellular matrix (ECM) 137, 178, 454
 extracellular signal-regulated kinase (ERK) peptides 467
- f**
- fatty acid amide hydrolase (FAAH) 297
¹⁸F-FDG 134, 138, 140, 142, 144, 147, 161
¹⁸F-FDG PET/CT imaging 135
¹⁸F-FET (fluoro-ethyl-tyrosine) 146
¹⁸F-fluoro-deoxy-L-thymidine (¹⁸F-FLT) 139
¹⁸F-6-Fluorodopa (¹⁸F-dopa) 146
¹⁸F-fluoromisonidazole (¹⁸F-FMISO) 137
 film-tension model 379
 filtered backprojection method 129
 firefly/beetle luciferin–luciferase reaction 70, 73, 75, 77, 78
 firefly bioluminescence 76, 78
 firefly luciferase (fLuc) 70–72, 74, 76, 78, 403
 FK506-binding protein 12 (FKBP12) 282
 fluorescence endoscope 63
 fluorescence imaging
 activatable probes 62–68
 detection in live animals 61–62
 drug development 68
 fluorescence molecules 58–61
 microscope 68
 fluorescence molecules 58–61
 fluorescence quantum yield 55, 56, 83
 fluorescence recovery after photobleaching (FRAP) 69
 fluorescence resonance energy transfer (FRET) 62
 fluorescently-labeled tetrazine 254
 fluorescent proteins 58, 59, 69, 71
 fluorine-18-labeled sodium fluoride (¹⁸F-NaF) 159, 160
 folate receptor (FR) 231, 284
 FP-biotin 297
 FP-Rho 297
 fragment-based ligand discovery (FBLD) approach 293
 FRET-based biosensors 69
 FRET self-quenching mechanism 62, 63
¹⁸F-THK5357 146
 fucosyltransferases (FUTs) 508
 furimazine substrate 81
- g**
- GABA_A receptor 284
⁶⁸Ga labeled somatostatin analogue 143
 galactose-based liver targeting 498
 galactose-based targeting 498, 506
 galactosylated albumin-based methods 496
 galactosylated liposomes 492, 496
 galactosylated poly-L-lysine (Gal-PLL) 497
 gastrin-releasing peptide receptor 196
⁶⁸Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-octreotate (⁶⁸Ga-DOTATATE) 142
 γ-CUBE
 PET imaging 158–161
 SPECT 155–156, 158
 γ-glutamyl-transpeptidase-activatable fluorescent probe 68
 gene expression 9, 14, 136–137
 germ-free mice 16–18
 glucagon-like peptide-1 (GLP-1) inhibitor 179, 381
 glutathione (GSH) 309, 340
 glu-ureido-based inhibitor 196
 glycan-labeled lymphocytes 513
 glycan-mediated targeting methods
 bacterial cells targeting 505–506
 cancer targeting 506–514
 immune system targeting 501–505
 liver and liver-based disease 491–501
 glycan pattern recognition 490, 491
 glycosaminoglycans 380
 glycosylated albumin ArMs. 341

- glyoxyl aldehyde-caged residues 311
 gnotobiotic mice 18
 gold and carbon nanoparticles 115
 gold-based protein bioconjugation 319
 gold nanoparticles (AuNPs) 442, 443
 gold nanorods (GNRs) 402, 442, 444
 gold/silica nanoparticles 141
 G protein-coupled receptors (GPCRs)
 86, 453
 green fluorescence 56
 green fluorescent protein 58, 68
- h**
- hairpin DNA (hpDNA) 410
 haloacetamides 293, 295, 296
 H-dimer quenching system 65
 hemagglutinating virus of Japan (HVJ)
 500
 heme 332, 335
 hepatic stellate cells (HSC) 500
 herpes simplex virus type 1 thymidine
 kinase (HSV1-tk) 136
 heterogeneous glycoalbumins 511,
 512
 2-(1-Hexyloxyethyl)-2-devinyl
 pyropheophorbide-a (HPPH)
 437
 high-frequency Doppler system 108
 high frequency preclinical ultrasound
 systems 103
 high frequency ultrasound imaging
 105, 106, 108, 109
 highly selective endogenous protein
 labeling 281
 HiLyte fluor 750 dye 265
 hollow gold nanoshells (HGNs) 443
 homogeneous glycoalbumins 511,
 512
 homopropargylglycine 313, 318
 HSC-targeted delivery 500, 501
 human carbonic anhydrases (hCAs)
 282
 hybrid mice 4–7
 hybrid PET/CT scanner 133
 hybrid PET/MRI system 134
 6-hydroxydopamine (6-OHDA) 174
 hydroxypropylmethyl cellulose acetate
 succinate (HPMCAS) 381
 5-hydroxytryptamine receptor 1A
 (5-HT1A) 146
 hypoxia 41, 137, 176, 381, 383
- i**
- ibrutinib 290
¹²⁵I-labeled CC49 diabody 261
¹²³I-labeled imidazo[1,2-*a*]pyridine
 derivative 174
¹²⁵I-labeled intact F(ab')₂ 174
 iminoboronate 300, 301
 immune system targeting
 alveolar macrophage targeting 503
 brain macrophage targeting
 504–505
 dendritic cells 504
 MPS cell-targeted delivery 501, 502
 peritoneal macrophage targeting
 503–504
 immunocompetent and
 immunodeficient mouse strains
 19
 inbred mice 4, 5
 indium-111-labeled
 atezolizumab-enhanced
 single-photon emission
 computed tomographic
 (SPECT)/computed tomographic
 (SPECT/CT) images 179
 indocyanine green (ICG) 65, 66
 inducible mutagenesis 13, 14
 inhalational administration 51
 inhaled agents 38
 injectable agents 38, 40
 [¹¹¹In]-labeled tetrazine 256
 inorganic nanoplatfoms 391
 inorganic scintillator crystals 130
 integrin $\alpha_v\beta_3$ 471
 internal radiation 185
 International Mouse Strain Resource
 (IMSR) website 16
 intracellular activatable probes 63
 intradermal administration 46, 49
 intragastric administration 42, 44
 intramuscular administration 46, 48

intranasal administration 46, 48
 intraperitoneal administration 45
 intratracheal administration 50, 51
 intravenous administration 46, 47
 intravenously injected microbubbles 120
 inverse electron demand Diels-Alder (IEDDA) chemistry 220
 bond-cleaving bio-orthogonal chemistry 260–265
 bond-cleaving bio-orthogonal ‘click-to-release’ chemistry 251, 253, 254
 pretargeting approach for cell imaging 252–256
 pretargeting approach for *in vivo* imaging 256–259
 reloadable materials allow local prodrug activation 265–272
 siRNA 272–274–276
 synthesis of new tetrazines and characterization 251, 252
 between *trans*-cyclooctene and tetrazine 249–250
 in vivo radio imaging 259–261
in vivo radio imaging 259–260
 iodine-123 (¹²³I) and iodine-131 (¹³¹I) 163, 171
 iodoacetamide (IA)-alkyne probe 293
 Ir-based ATHase 337
 iridium-based ArMs 337
 iron oxide colloidal platforms 391
 iron oxide nanoparticles (IONPs) 141
 isoflurane 38, 40, 106, 116
 isonitrile 223

j

Jcl+ICR 8

k

ketamine 40
 ketone-bearing monosaccharide *N*-levulinoyl mannosamine (ManLev) 213
 ketone-focused experiments 215
 keto-phenolate-oxyluciferin 71
 Kupffer cells 500

l

labeled target compounds 191–192
 label tissues or organs *in vivo*, 229
 laboratory mice
 animal identification 24
 breeding systems and mating systems 19–20
 closed colony 8
 congenic strains 8
 cre-loxP system 14, 15
 CRISPR/Cas9 system 16, 17
 developmental milestones 24
 germ-free mice 16–18
 gestation period 21
 gnotobiotic mice 18
 growth of pups 22–23, 25
 hybrid mice 4–7
 immunocompetent and immunodeficient mouse strains 19
 inbred mice 4, 5
 inducible mutagenesis 13, 14
 mating behavior 21, 22
 mouse health-monitoring 19
 origin and history of 2–3
 outbred stocks 8
 parental behavior and rearing pups 21–22
 parturition 21
 in preclinical research 24–28
 production planning 19
 record keeping and colony organization 23–24
 reproductive and developmental parameters 23
 reproductive lifespan 23
 resources 16
 specific-pathogen-free (SPF) mouse strains 18
 spontaneous mice 9
 targeted mutagenesis 11–13
 transgenesis 9–11
 wild-derived mice 3
 lactosaminated albumin-based anticancer strategy 497
 lactosaminated albumin-based methods 496

- ligand-directed acyl imidazole (LDAI) chemistry 284–286
 - ligand-directed chemical labeling
 - endogenous protein labeling 287, 288
 - ligand-directed acyl imidazole (LDAI) chemistry 284–286
 - ligand-directed tosyl (LDT) chemistry 282–284
 - targeted covalent inhibitors 287–301
 - ligand-directed chemistry using *N*-acyl-*N*-alkyl sulfonamide (LDNASA) 287
 - ligand-directed labeling 281
 - ligand-directed tosyl (LDT) chemistry 282–284
 - ligands 112, 136, 143, 186, 190, 231, 295, 299, 379, 380
 - ligand-targeted liposome-based strategy 231
 - light-induced oxidation 434–436
 - light-sensitive liposomes 434
 - linearized transgenes 10
 - linear probe 105, 107–109, 113, 115
 - lintuzumab 197
 - lipid-coated mesoporous silica NPs 392
 - lipidic nanoplatfoms 384–389
 - lipid solid nanoparticle 141
 - lipophilic chelator 141
 - liposomes 141
 - light-sensitive 434
 - light-triggered release
 - light-induced oxidation 435–436
 - photocleavage 440–442
 - photocrosslinking 436–438
 - photoisomerization 438–440
 - photothermal release 442–444
 - liver and liver-based disease
 - nonparenchymal cell targeting 498–501
 - parenchymal cells targeting 492–498
 - local prodrug activation 265–272
 - low-density lipoprotein receptor-related protein (LRP) 380
 - lower than the critical solution temperature (LCST) 415
 - luciferase-based bioluminescence probes 84–86
 - luminescence imaging 55, 56
 - chemiluminescence system 82–84
 - coelenterazine-dependent luciferase system 76–82
 - detecting in live animals 84
 - firefly/beetle luciferin–luciferase reaction 70–76, 78
 - luciferase-based bioluminescence probes 84–86
 - luteinizing hormone (LH)-releasing hormone (LHRH) 453
 - lutetium silicate oxide (LSO) 129
 - lutetium–yttrium oxyorthosilicate (LYSO) scintillators 156
 - lymphangiography 58
- m**
- macrophages or leukocyte-coated particles 393
 - magnetic resonance imaging (MRI) 473–474
 - mannose-6-phosphate (M6P) 500
 - mannose-6-phosphate/insulin-like growth factor (M6P/IGF-II) receptor 508
 - mannose receptor (ManR) 457, 498, 501, 507
 - mannosylated liposomes 499, 503, 504, 506
 - mating behavior of mice 21, 22
 - 9 MBq ¹²³I 158
 - mesoporous silica nanoparticles (MSNs) 392, 405
 - meta-[²¹¹At]astatobenzylguanidine (MABG) 192
 - metabolically label cells *ex vivo*, 227–229
 - metabolic glycan engineering
 - bioorthogonal chemistries 216–223
 - covalent delivery of therapeutics in mice 236–237
 - imaging glycans in mice 234–236
 - origin of 210–213

- permissive carbohydrate biosynthetic pathways 223–226
- plants 240
- schematic of 210
- systemic administration of an unnatural sugar 226
- testbed for bioorthogonal chemistries 240
- unnatural functional groups and bioorthogonal elaboration 213–216
- worms 239
- zebrafish 237–239
- metabolic probe 134–135
- metal complex catalyst
- bond-cleavage reactions 324–332
 - bond formation 319–324
 - microdevices 310
 - microspheres 310
 - nanoparticles 310
 - protein bioconjugation 311–319
 - protein decaging 310–311
 - resins 310
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 174
- M13 filamentous phage 454
- mice-bearing colon carcinoma xenografts (LS174T) 262
- mice-bearing ovarian carcinoma xenografts (OVCAR-3) 262
- micelles 141, 379, 467, 474
- Michael acceptors 282, 290–293
- microbubble contrast agents 116
- micro-CT scanner 133, 156
- microenvironment probe 137–138
- micro-MRI system 133
- microscope 58, 61, 68
- middle cerebral artery occlusion (MCAO) model 176
- minigastrin 196–197
- Mn-based ArMs 337
- molecular imaging 58, 59, 65, 69, 127, 136, 151, 200, 202
- monoacylglycerol lipase (MAGL) 297
- monomethyl auristatin E (MMAE) 260, 331
- monomethyl auristatin F (MMAF) 466
- mononuclear phagocyte system (MPS) 501
- monosaccharide scaffolds 216, 223–225
- monosaccharide substrates via liposomes 231–234
- mouse health-monitoring 19
- mouse strains
- closed colony 8
 - congenic strains 8
 - hybrid mice 4–7
 - inbred mice 4, 5
 - outbred stocks 8
 - wild-derived mice 3
- MPS cell-targeted delivery 501, 502
- ^{99m}Tc-diethylenetriamine pentaacetic acid (^{99m}Tc-DTPA) complex 176
- ^{99m}Tc-labeled Bn-IDA 166
- mucin-type O-linked glycans 224
- mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) inhibitor MI-2 293
- multiple-hole pinhole collimator 152
- mutant mice
- cre-loxP* system 14, 15
 - CRISPR/Cas9 system 15–16
 - inducible mutagenesis 13
 - spontaneous mice 9
 - targeted mutagenesis 11–13
 - transgenesis 9–11
- myeloid cell leukemia 1 (Mcl-1) 301
- myocardial ischemia 177–178
- myocardial perfusion imaging (MPI) 140
- n**
- N*-acetyl-D-fucose (D-FucNAc) 225
- N*-acetylgalactosamine (GalNAc) analog peracetylated *N*-azidoacetyl galactosamine (Ac₄GalNAz) 224
- N*-acetyl muramic acid (MurNAc) 225
- NanoLuc 81
- NanoLuc luciferase 81

- nanomedicine platforms
 - biomimetic or cell-derived
 - nanosystems 393–394
 - examples of 385
 - inorganic nanoplatforms 391–393
 - lipidic nanoplatforms 384–389
 - polymer-based nanoplatform
 - 389–391
 - type of 388
 - nanomedicines 373, 375, 381
 - nano-palladium anticancer therapy 333
 - nanoparticles (NPs) 140
 - administration route 384
 - applications 373, 374
 - enhanced permeation and retention effect 374
 - intravenous (i.v.) administration 373
 - physicochemical properties 375–379
 - stimuli-responsive nanomaterials 381–383
 - surface functionalization 379–381
 - National Center for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) 33
 - natural amino acids 281, 311, 319, 458
 - natural ligands 452–454
 - naturally occurring metals 332
 - natural metalloenzymes 309
 - natural monosaccharide 209–211, 223, 225, 240, 491, 506–508
 - natural monosaccharide-based methods 506–508
 - N*-azidoacetylmannosamine (ManNAz) 215
 - NB-PC drug release 440, 441
 - N*-butanoyl mannosamine (ManBut) 211
 - near-infrared dye-conjugated
 - atezolizumab 179
 - near-infrared (NIR) light-mediated theranostics 402
 - near-infrared (NIR) light-responsive theranostics
 - drug delivery approach 411–415
 - PDT 415–419
 - PTT approach 419–421
 - needle gauge 37
 - NeoBOMB 1 196
 - neomycin (Neo) 11
 - nesiritide 464
 - NeutrAvidin 235
 - NIR-absorbing phthalocyanines 436
 - NIR Cy 5.5 flurophore 62
 - NIR-emitting fluorescent proteins 71, 78
 - NIR fluorescent labeled probe 57
 - non-invasive animal imaging 56
 - nonparenchymal cell targeting 498–501
 - non-targeted microbubbles 104, 110
 - N*-succinimidyl 3-[²¹¹At]astatobenzoate (SAB) 192
 - N*-succinimidyl 3-[²¹¹At]-astato-4-guanidinomethylbenzoate (SAGMB) 193
 - N*-succinimidyl 3-(tri-*n*-butylstannyl)benzoate 192
 - nuclear localization signal (NLS) 469
- O**
- octadecanol 469
 - octreotide 187, 467
 - O*-GlcNAc-modified proteins 224
 - one-bead one-peptide (OBOC) libraries 458, 459
 - one-handed mouse restraint 34, 35
 - O*-nitrobenzoxadiazole (*O*-NBD) 287
 - o*-nitrobenzyl (ONB) 403, 404, 440
 - Oplophorus* luciferase mutant 81
 - optical imaging
 - advantages and disadvantages 58
 - luminescence 55–56
 - wavelength of luminescence 56–57
 - o*-quinone-methides 222, 223
 - oral administration 34, 42, 44, 290, 293, 295, 373, 380, 384
 - ordered subset expectation
 - maximization (OSEM) iterative method 129
 - organic compounds 58, 59, 202, 357

- osimertinib 290
- outbred stocks 8
- oxy and deoxy hemoglobin
near-infrared absorption spectra
114
- oxy-/deoxy-hemoglobin 56, 57, 114,
120
- oxyluciferin 70, 71
- p**
- paclitaxel (Taxol) 403
- paclitaxel-octadecanol conjugation
(PTX-ODN) nanoparticle 469
- palladium catalysis 318
- palladium nanoparticles (Pd-NPs) 331
- parenchymal cells targeting 492–494,
499
- parenteral administration 37, 42–53
- Parkinson's disease 146, 174–176, 362,
457
- pasireotide 453
- patient-derived tumor xenograft (PDX)
models 25
- patient-derived xenograft (PDX) models
457
- PEGylation 377, 383
- pentixather 196
- pepsinogen 310
- peptide–drug conjugates 460,
465–467, 474
- peptide hormones 464, 467
- peptide microarrays 452, 459, 460
- peptide receptor radionuclide therapy
(PRRT) 135, 143
- peptides 195, 196
- peptide transporter 1 (PEPT1) 459
- peracetylated
N-azidoacetylgalactosamine
(Ac₄GalNAz) 217
- peracetylated sugars 225
- perfusion probes 140
- peritoneal macrophage targeting
503–504
- permissive carbohydrate biosynthetic
pathways
- deployment of unnatural
monosaccharides in mammalian
cells 223–225
- unnatural sugars that label glycans on
bacterial cells 225–226
- personalized (or precision) medicine
(PM) 142
- personal treatment screening 142–143
- PeT-based fluorophores 65
- PeT mechanism 65, 67
- pH-activatable PeT system 65
- phage-display peptide library screening
454, 455
- pHCT74 peptide 468
- pH (low) insertion peptides (pHLIP
peptides) 138
- phosphate buffered saline (PBS) 35,
255
- phosphatidylcholine (PC) 435, 440,
442, 500
- photoacoustic imaging 112–114
technique 105
- photoactivatable drug release methods
434
- photoactivatable targeting methods
NIR light-responsive theranostics
drug delivery approach 411–415
PDT 415–419
PTT 419–421
UV light-responsive theranostics
photocaged strategy 403–405
photoisomerization 405–408
visible light-responsive theranostics
408–410
- photoaffinity labeling 282
- photocaged strategies 403, 404
- photocleavable liposomes 440
- photocleavage liposomes 440
- photocrosslinking liposomes 436–438
- photodynamic therapy (PDT) 401,
415–419, 433
- photoinduced electron transfer (PeT)
system 65
- photoisomerization liposomes 438
- photoisomerization strategy 405–408
- photoluminescence 55, 56, 394

- photon-induced electron transfer (PeT) 62
- photosensitizer (PS) 236, 391, 411, 435
- photothermal conversion agents (PTCAs) 419
- photothermal therapy (PTT) 391, 401, 419–421
- pH-responsive and mucoadhesive nanomedicine 381
- piezoelectric elements 103
- pinhole collimator 152
- poly(ethylene glycol) (PEG) 465, 468
- poly(*t*-histidine) 383
- polyamidoamine (PAMAM) 503
- poly(amidoamine)-*b*-poly(aspartic acid)-*b*-poly(ethylene glycol) (PAMAM-PA_{sp}-PEG) 468
- polycaprolactone-tagged coumarin chlorambucil (PCL-CC) probe 405
- polyethylene glycol (PEG) 377, 381, 434, 441
- poly-L-lysine (PLL) 496, 497
- polylysine polymer 62
- polymer-based nanoplatfrom 389–391
- polymeric nanoparticles 141, 324, 469
- porous silicon (PSi) 380, 393
- porphyrin-phospholipid (PoP) 411, 435
- position-sensitive optically transparent scintillation crystal 129
- positron emission tomography (PET)
 - biological processes 138–140
 - brief history of 128–129
 - cardiology model 145–146
 - gene expression 136–137
 - image analysis 147–148
 - metabolic probe 134–135
 - microenvironment probe 137–138
 - nanoparticles 140–141
 - neurology model 146–147
 - oncology model 141–142
 - other disease model 147
 - perfusion probes 140
 - principles of 129–133
 - small animal PET scanner 133–134
 - specific enzyme substrate 137
 - specific receptor targeting probes 135–136
 - targeting peptides 471–472
- positron radionuclides 128
- precision medicine 200
- preclinical benchtop imagers 155
- preemptive analgesia 37–39
- pretargeting approach
 - for cell imaging 252–256
 - for *in vivo* imaging 256–259
 - in vivo* radio imaging 259–260
- pretargeting method 189
- p90 ribosomal protein S6 kinase (RSK2-CTD) 293
- probes 162, 163
- procarboxypeptidase 310
- Proc groups 324
- proenzymes 310
- programmed death receptor 1 (PD-L1) 178
- propargyl moiety 326
- propargyloxy carbamates 324
- propargyloxycarbonyl (Proc)-caged lysine residues 311
- prostate-specific antigen (PSA) protease 229
- prostate-specific membrane antigen (PSMA) 145, 189
- protein bioconjugation 311, 314
- protein decaging 310, 312
- protein disulfide isomerase (PDIA1) 293
- 14-3-3 protein zeta 282
- proton sponge effect 378
- prototypal photoacoustic systems 113
- pseudaminic acid 225
- PSMA-617 196
- PSMA negative PC3 flu tumors 190
- PSMA positive PC3 PIP tumors 190
- pulsed Doppler 103, 108, 116
- pulse inversion imaging 111
- pulse repetition frequency (PRF) 107, 108
- putative firefly/beetle bioluminescence reaction 70
- pyrenylmethyl ester 403, 404

q

quantum dot (Qdot) 59

quantum dots 141

rradioiodinated A β probes 173

radiolabeling

Alzheimer's disease 173–174

aromatic electrophilic substitution
reaction 171–172

atherosclerotic plaque 177

cancer imaging 178–179

cerebral ischemia 176–177

characteristics of 164

iodine-123 and iodine-131 171

myocardial ischemia 177–178

Parkinson's disease 174–176

small molecular compounds 171

strategy

²¹¹At-labeled compounds
192–193labeled target compounds
191–192

technetium 99m 164–171

radionuclide therapy 162

antibodies 197

²¹¹At-labeled compounds 192–193 β -emitting nuclides 186–188 α -emitting nuclides 188–190

labeled target compounds 191, 192

peptides 195–197

radiotheranostics 200–205

radiotheranostics

BNCT 203–204

4-borono-L-phenylalanine (BPA)
204expectations and challenges
202–203

precision medicine 200

probe 200–202

probe development 202

sodium borocaptate (BSH) 204–205

radiotherapy planning 142, 144

Rayleigh–Plesset equation 110

reactive oxygen species (ROS) 65, 76,
186, 236, 364, 391, 435, 499

real-time lymphatic imaging 61

red fluorescent proteins (RFPs) 71

red-shifted bioluminescence system
71red-shifted coelenterazine-dependent
luciferase systems 80

refinement 33, 157, 215

reloadable materials, allow local

prodrug activation 265–272

representative cyclooctyne scaffolds
218resonance-type microwave reactor
169

restraint

one-handed mouse 34, 35

two handed 34, 36

reticuloendothelial system (RES) 434,
501

retro-orbital administration 52–53

reversible covalent BTK inhibitor 293

rhodamine bisazide probe 331

rhodium-based ArMs 335

rhodium catalysts 313

ring-opening metathesis polymerization
(ROMP) 337

rituximab 197, 258

Ru(II)-dipyridophenazine (dppz)
compounds 410

ruthenium (Ru) 408

ruthenium catalyst [Cp*₂Ru(cod)Cl]
311ruthenium-catalyzed olefin metathesis
318**S**

semi-conductor nanoparticles 58, 59

senescence-associated secretory
phenotype (SASP) 140

serine hydrolases 297

sialic acid 211

biosynthetic pathway 213

precursors 227

Sialyl–Lewis X-based liposomes 508

siglec-targeting ligands 508, 510

silver NPs 391

single-chain polymeric nanoparticles
(SCPNS) 324

- single-photon emission computed tomography (SPECT)
 - animal monitoring 157
 - β -CUBE 156, 158, 160
 - γ -CUBE 155–156
 - human brain-specific SPECT device 152, 153
 - multiple-hole pinhole collimator 152
 - probes 162, 163
 - radionuclides 162
 - small-animal SPECT devices 153, 154
 - tumor-bearing mice 152
 - X-CUBE 156, 161
 - siRNA 273, 275, 276
 - small animal PET scanner 128, 133–134
 - small molecular compounds 171
 - sodium borocaptate (BSH) 204, 205
 - sodium iodide scintillator 129
 - solid lipid NPs (SLNs) 384, 388, 507
 - somatostatin analog peptide octreotide 187
 - somatostatin receptors (SSTR) 136, 142, 195, 453, 467
 - sorafenib 380, 390, 497
 - spatial resolution 106, 131
 - specific enzyme substrate 137
 - specific-pathogen-free (SPF) mouse strains 18
 - specific receptor targeting probes 135–136
 - SPECT 2000H-40 152, 153
 - spiropyran (SP) 405, 406, 408, 412
 - based monomer 408
 - spontaneous mice 9
 - Src homology 2 (SH2) domain 282
 - standardized uptake value (SUV) 147
 - Staudinger ligation 215–217, 219, 227, 235, 240
 - stemness 139
 - stimulator of interferons genes (STING) 388
 - stimuli-responsive nanomaterials 381–383
 - stimuli-responsive strategies 401
 - strain imaging 116
 - strain-promoted alkyne-azide cycloaddition (SPAAC) 249
 - strain-promoted azide-alkyne cycloaddition (SPAAC) 216
 - streptavidin 326, 335, 337, 458
 - streptococcal adhesin P (SadP) protein 505
 - subcutaneous administration 44, 45
 - substances
 - characteristics 34–35
 - frequency and volume of administration 36–37
 - needle size 37
 - vehicle characteristics 35–36
 - sulforhodamine B (SRB) 435
 - sulfur (VI) fluorides 297, 299
 - superparamagnetic iron oxide (SPIO) nanoparticles 273, 474
 - surface functionalization, NPs 379–381
 - synthetic peptide library screening 458–460
 - synthetic sugars 508–511
- t**
- TAG72 antigen 256
 - targeted and non targeted microbubbles 110
 - targeted covalent inhibitors (TCIs)
 - activated esters 295–297
 - advances in TCI chemistry 287
 - amides 295–297
 - carbamates 295–297
 - haloacetamides 293–296
 - Michael acceptors 290–294
 - potential advantages 287
 - sulfur (VI) fluorides 297–300
 - ureas 295–297
 - warheads and reactions 300–301
 - targeted mutagenesis 11–13
 - targeting peptides
 - drug delivery
 - peptide-drug conjugates 465–467
 - peptide-targeted nanoparticles 467–469
 - identification of

- natural ligands or biomimetics 452–454
 phage-display peptide library screening 454–458
 synthetic peptide combinatorial library 458–460
 MRI 473
 optical imaging
 integrin $\alpha_v\beta_3$ -RGD tripeptide targeting probes 471–472
 near infrared imaging 472
 targeted affinity probes for tumor imaging 471
 PET 472
 therapeutic peptides 460, 461
 naturally occurring peptides 464
 peptide conjugates 464–465
 TCO-Gel 266, 268
 TCO-modified rituximab (Rtx-TCO) 258
 technetium 99m 164–171
 temporal resolution 103, 107, 132, 145
 “tet-on/tet-off” system 13
 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 142, 170, 193
 tetrazine (Tz) 250
 tetrazine-Cy3 probe 222
 therapeutic effect monitoring 140, 143–144
 thermosensitive liposomes (TSL) 442
 three-dimensional printed biocompatible scaffolds 161
 thymidine kinase (TK) 11, 136, 139
 thymidine monophosphate (TMP) 139
 tissue-specific enzymes 229–231
 tissue-specific transporters 234
 T7 lytic phage 454
 toll-like receptors (TLRs) 19, 390
 traceless labeling 282, 284
 trans-activating transcriptional activator (TAT) peptides 466
 transcription activator-like effector nucleases (TALEN) 15
trans-cycloalkenes 223
trans-cyclooctene (TCO) 220, 223, 249–250
 transferrin receptor (TfR) 187
 transgenesis 9, 10
 transgenic mice expressing fluorescent protein 68
trans-sila-cycloheptene 223
 Trastuzumab 63, 197
 Trastuzumab-Alexa680 64
 Trastuzumab-AlexaFluor680 63
 trastuzumab-Cy5.5 63
 trehalose 225, 227, 505
 1,4,7-triazacyclononane-*N,N',N''*-triacetic acid (NOTA) 193
 tricuspid annular plane systolic excursion (TAPSE) 116
 triphenyl phosphonium (TPP) 469
 Triumph LabPET12/SPECT4/CT 152, 153, 170
 trypsinogen 310
 tumor-associated glycoprotein-72 (TAG72) 260
 tumor-associated macrophages (TAMs) 457, 507
 tumor microenvironment 178, 186, 331, 392, 457, 507
 two-dimensional B-mode image 109
 two handed restraint 34, 36
 [Tyr3]-octreotide (TOC) 195–196
 tyrosine kinase 6 (PTK6) 136
- U**
- ubiquitin-like modifier activating enzyme 5 (UBA5) 293
 ultrasound contrast technology 104
 ultrasound imaging
 applications 104
 cardiovascular applications 115–120
 contrast agents 109–112
 developmental biology 121–123
 high frequency 105–109
 non-targeted microbubbles 104
 oncology 120–121
 photoacoustic imaging 112–115
 ultrasound probes 103, 105
 unit-bound molecular probes 202
 unnatural amino acids (UAAs) 281, 311, 458

- unnatural monosaccharides deployment
 - in mammalian cells 223, 224
- unnatural sugar
 - carbohydrate biosynthetic pathways 227
 - label tissues or organs in vivo 229
 - metabolically label cells ex vivo 227–229
 - monosaccharide substrates via liposomes 231–234
 - that label glycans on bacterial cells 226
 - tissue-specific enzymes 229–231
 - tissue-specific transporters 234
- unnatural sugars, label glycans on bacterial cells 225–226
- upconversion nanoparticles (UCNPs) 401, 411, 412, 414
- ureas 295–298, 309
- U-SPECTII 152, 153
- UV light-responsive theranostics
 - photocaged strategy 403–405
 - photoisomerization 405–408
- V**
 - vascular imaging 58
 - vehicle characteristics 35–36
 - vinyl sulfides 223
 - visible light-responsive theranostics 408–410
 - vitamins 379, 380
 - VivoRen 82
- W**
 - warheads and reactions 300–301
 - wave intensity analysis 116
 - wild-derived mice 3
 - worms 219, 237, 239, 241
- X**
 - xanthene-based NIR fluorophore 65
 - xanthene fluorophore 63
 - X-CUBE
 - CT imaging 161–162
 - SPECT 156
 - xylazine 40
- Y**
 - ⁹⁰Y-labeled anti- $\alpha_6\beta_4$ antibody (⁹⁰Y-ITGA6B4) 187
 - ⁹⁰Y-labeled antibody (⁹⁰Y-OTSA101) 188
- Z**
 - zebrafish 237
 - zinc finger nucleases (ZFN) 15
 - zonula occludens toxin (Zot) 469
 - zwitterionic cyanine fluorophore 59
 - zymogens 310